Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pluri Inc PLUR

Healthcare Biotechnology
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.


NDAQ:PLUR - Post by User

Pluri Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(76)
•••
Post by lucaM1on May 03, 2022 9:06am
68 Views
Post# 34650517

Cell and Gene Therapy Thawing Equipment Market report

Cell and Gene Therapy Thawing Equipment Market report

Cell and Gene Therapy Thawing Equipment Market Research Report 2022 Cumulative Impact of COVID-19

Top companies in the market:
Pluristem Therapeutics, Genesis BPS, Eppendorf, Cytiva (A subsidiary of Danaher Corporation), Glenmark Pharmaceutical



https://mathandling.com.au/news/1070008/cell-and-gene-therapy-thawing-equipment-market-research-report-2022-cumulative-impact-of-covid-19-pluristem-therapeutics-genesis-bps-eppendorf-cytiva-a-subsidiary-of-danaher-corporation-glenma/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities